Compare immunosuppressant medicines for eye-only myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 74 years old
- Have MG that affects eye muscles (ocular MG), not the whole body
- Have proof supporting MG, such as specific antibody tests or abnormal nerve/nerve-muscle test results
- Be willing to do blood/other sample tests, imaging (like chest CT), and repeated nerve tests, and keep up with follow-ups
- If you can become pregnant: have a negative pregnancy test and use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This study tests an investigational medication called rozanolixizumab for people who have ocular myasthenia gravis (MG), where weakness is only in the eye muscles. The medicine is given as an injection under the skin and may help improve symptoms like drooping eyelids or double vision.
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
This study compares two treatments for myasthenia gravis (a nerve-muscle condition causing weakness) that occurs with a thymoma (a tumor in the thymus). You will receive one of two medicines before surgery to remove the thymoma, to see which better improves muscle strength and daily function.
Hear when a new Ocular Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.